Integrated BioPharma, Inc. reported a net income of $611,000 for the three months ended March 31, 2025, compared to a net income of $285,000 for the same period in 2024. For the nine months ended March 31, 2025, the company achieved a net income of $986,000, a significant turnaround from a net loss of $156,000 in the prior year. The company's revenue for the three months increased by 6.1% to $13.9 million, while for the nine months, revenue rose by 6.9% to $40.2 million, driven by growth in both its Contract Manufacturing and Other Nutraceuticals segments.
The financial performance reflects a notable improvement in operating income, which rose to approximately $739,000 for the three months ended March 31, 2025, compared to an operating loss of $1,431,000 in the same quarter of the previous year. The increase in operating income for the nine-month period was even more pronounced, with a reported operating income of $1.4 million, up from a loss of $151,000. The gross profit margin also improved, rising from 6.9% to 10.2% of net sales, attributed to increased sales volumes and effective cost management.
Operationally, Integrated BioPharma has seen a shift in its customer base, with approximately 85% of its consolidated net sales in the latest quarter derived from two major customers, Life Extension and Herbalife. This concentration represents a slight decrease from 90% in the previous year, indicating a diversification effort. The company has also reported an increase in international sales, which rose to $3.2 million for the three months ended March 31, 2025, compared to $1.98 million in the same period last year.
In terms of strategic developments, Integrated BioPharma has focused on enhancing operational efficiency and reducing costs. The company has maintained its selling and administrative expenses at approximately $812,000 for the three months ended March 31, 2025, compared to $893,000 in the prior year. The company’s cash position improved significantly, with cash at the end of the reporting period totaling $2.96 million, up from $2.02 million a year earlier. Looking ahead, Integrated BioPharma aims to continue expanding its customer base while managing costs effectively, although it acknowledges potential challenges from inflation and competitive pressures in the market.
About INTEGRATED BIOPHARMA INC
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.